Article Versions Notes

Adams AC, Borden ES, Macy AM, Thomson N, Cui H, Gimbel MI, Wilson MA, Buetow KH, Roe DJ, DiCaudo DJ, et al. High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. Cancers. 2022; 14(9):2200. https://doi.org/10.3390/cancers14092200

Adams, Anngela C., Elizabeth S. Borden, Anne M. Macy, Nick Thomson, Haiyan Cui, Mark I. Gimbel, Melissa A. Wilson, Kenneth H. Buetow, Denise J. Roe, David J. DiCaudo, and et al. 2022. "High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition" Cancers 14, no. 9: 2200. https://doi.org/10.3390/cancers14092200

Adams, A. C., Borden, E. S., Macy, A. M., Thomson, N., Cui, H., Gimbel, M. I., Wilson, M. A., Buetow, K. H., Roe, D. J., DiCaudo, D. J., Homsi, J., & Hastings, K. T. (2022). High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. Cancers, 14(9), 2200. https://doi.org/10.3390/cancers14092200